Aarti Pharmalabs Statistics

Total Valuation

NSE:AARTIPHARM has a market cap or net worth of INR 82.40 billion. The enterprise value is 85.97 billion.

Market Cap	82.40B
Enterprise Value	85.97B

Important Dates

The last earnings date was Monday, May 12, 2025.

Earnings Date	May 12, 2025
Ex-Dividend Date	Feb 14, 2025

Share Statistics

NSE:AARTIPHARM has 90.63 million shares outstanding. The number of shares has increased by 0.05% in one year.

Current Share Class	90.63M
Shares Outstanding	90.63M
Shares Change (YoY)	+0.05%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	28.82%
Owned by Institutions (%)	20.63%
Float	48.14M

Valuation Ratios

The trailing PE ratio is 30.27.

PE Ratio	30.27
Forward PE	n/a
PS Ratio	3.90
PB Ratio	4.14
P/TBV Ratio	4.36
P/FCF Ratio	n/a
P/OCF Ratio	24.85
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.51, with an EV/FCF ratio of -121.99.

EV / Earnings	31.56
EV / Sales	4.06
EV / EBITDA	18.51
EV / EBIT	22.78
EV / FCF	-121.99

Financial Position

The company has a current ratio of 2.01, with a Debt / Equity ratio of 0.21.

Current Ratio	2.01
Quick Ratio	1.11
Debt / Equity	0.21
Debt / EBITDA	0.89
Debt / FCF	-5.86
Interest Coverage	14.03

Financial Efficiency

Return on equity (ROE) is 14.54% and return on invested capital (ROIC) is 10.61%.

Return on Equity (ROE)	14.54%
Return on Assets (ROA)	8.60%
Return on Invested Capital (ROIC)	10.61%
Return on Capital Employed (ROCE)	16.78%
Revenue Per Employee	10.10M
Profits Per Employee	1.30M
Employee Count	2,095
Asset Turnover	0.77
Inventory Turnover	1.83

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +57.76% in the last 52 weeks. The beta is -0.41, so NSE:AARTIPHARM's price volatility has been lower than the market average.

Beta (5Y)	-0.41
52-Week Price Change	+57.76%
50-Day Moving Average	779.10
200-Day Moving Average	689.67
Relative Strength Index (RSI)	64.30
Average Volume (20 Days)	534,075

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NSE:AARTIPHARM had revenue of INR 21.15 billion and earned 2.72 billion in profits. Earnings per share was 30.04.

Revenue	21.15B
Gross Profit	9.87B
Operating Income	3.77B
Pretax Income	3.61B
Net Income	2.72B
EBITDA	4.64B
EBIT	3.77B
Earnings Per Share (EPS)	30.04

Full Income Statement

Balance Sheet

The company has 562.06 million in cash and 4.13 billion in debt, giving a net cash position of -3.57 billion or -39.38 per share.

Cash & Cash Equivalents	562.06M
Total Debt	4.13B
Net Cash	-3.57B
Net Cash Per Share	-39.38
Equity (Book Value)	19.90B
Book Value Per Share	219.62
Working Capital	6.65B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.32 billion and capital expenditures -4.02 billion, giving a free cash flow of -704.76 million.

Operating Cash Flow	3.32B
Capital Expenditures	-4.02B
Free Cash Flow	-704.76M
FCF Per Share	-7.78

Full Cash Flow Statement

Margins

Gross margin is 46.67%, with operating and profit margins of 17.85% and 12.88%.

Gross Margin	46.67%
Operating Margin	17.85%
Pretax Margin	17.05%
Profit Margin	12.88%
EBITDA Margin	21.96%
EBIT Margin	17.85%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 3.50, which amounts to a dividend yield of 0.38%.

Dividend Per Share	3.50
Dividend Yield	0.38%
Dividend Growth (YoY)	75.00%
Years of Dividend Growth	2
Payout Ratio	11.64%
Buyback Yield	-0.05%
Shareholder Yield	0.33%
Earnings Yield	3.31%
FCF Yield	-0.86%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a